BPG is committed to discovery and dissemination of knowledge
Opinion Review
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Jul 21, 2026; 32(27): 119356
Published online Jul 21, 2026. doi: 10.3748/wjg.119356
Is metabolic dysfunction-associated steatotic liver disease truly irrelevant? Unmasking the heterogeneity and confounders in pancreatic cancer outcomes
Zhe-Kun Xiong, Yu-Zi Jiang, Yan-Hua Lin, Jian-Dong Cao, Tao-Ying Deng, Yi-Yuan Zheng
Zhe-Kun Xiong, Yan-Hua Lin, Jian-Dong Cao, Tao-Ying Deng, Department of Spleen, Stomach and Hepatobiliary, Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan 528401, Guangdong Province, China
Yu-Zi Jiang, Yi-Yuan Zheng, Laboratory Center, Department of Hepatopathy, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai 200071, China
Co-first authors: Zhe-Kun Xiong and Yu-Zi Jiang.
Author contributions: Zheng YY conceived this work; Xiong ZK and Jiang YZ contributed equally as co-first authors; Xiong ZK, Jiang YZ, Lin YH, Cao JD, and Deng TY researched the literature and wrote the manuscript; all authors thoroughly reviewed and endorsed the final manuscript.
AI contribution statement: AI tools were used solely for language editing and translation support. ChatGPT assisted in improving the clarity and grammar of the English text. The scientific content, data analysis, interpretation, and conclusions were developed entirely by the authors. The authors reviewed and approved all AI-assisted modifications and assume full responsibility for the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Yi-Yuan Zheng, PhD, Laboratory Center, Department of Hepatopathy, Shanghai Municipal Hospital of Traditional Chinese Medicine, No. 274 Zhijiang Middle Road, Shanghai 200071, China. iceroser@126.com
Received: January 26, 2026
Revised: February 25, 2026
Accepted: March 24, 2026
Published online: July 21, 2026
Processing time: 163 Days and 10.9 Hours
Core Tip

Core Tip: This article challenges the conclusion that metabolic dysfunction-associated steatotic liver disease is irrelevant to pancreatic cancer outcomes. We argue that the reported lack of association stems from the use of noninvasive surrogates that fail to capture the complexity of metabolic inflammation in cachectic patients. By ignoring the heterogeneity of metabolic dysfunction-associated steatotic liver disease and the statistical impact of competing risks, current analyses likely underestimate the pro-metastatic potential of the fibrotic liver niche. Furthermore, by contrasting these limitations with mechanistic evidence of a pre-metastatic niche, we emphasize that statistical absence of correlation does not equal biological absence of causation, advocating for fibrosis-focused future research.

Write to the Help Desk